At the end of the session, the participants will be able to:
- Understand threshold models as a surrogate for paclitaxel-related hematological and non-hematological toxicity
- Understand steady-state plasma concentrations as a surrogate for 5FU-related toxicity and clinical activity
- Know logistical issues and practical issues that have to be dealt when performing TDM of 5FU
This Session will discuss therapeutic drug monitoring (TDM) of paclitaxel and 5FU in patients with solid tumors. Threshold models have been used retrospectively to describe the relationship between 3-weekly paclitaxel pharmacokinetics and hematological as well as non-hematological toxicity. Only recently, the clinical value of TDM of 3-weekly paclitaxel is undergoing prospective testing. With 5FU, several non-randomized and one randomized study suggest a clinical benefit from TDM. Still, some logistical and practical issues have to be considered when implementing TDM of continous-intravenous 5FU.